Resha Rajkarnikar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Resha Rajkarnikar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Karthikeyan Mythreye
University of Alabama at Birmingham 6 Department of Pathology and O'Neal Comprehensive Cancer Center, Heersink School of Medicine Birmingham, Alabama
42 shared publications - Christen A. Khella
Rutgers Cancer Institute of New Jersey, New Brunswick, USA
40 shared publications - Lorna Rodriguez-Rodriguez
14Division of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Los Angeles, California
40 shared publications - Lucyann Franciosa
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
40 shared publications - Michael L. Gatza
Rutgers Cancer Institute of New Jersey, New Brunswick, USA
40 shared publications - Asha Kumari
Department of Pathology, University of Alabama at Birmingham, Birmingham, Heersink School of Medicine, Birmingham, Alabama, USA
2 shared publications
Latest Publications
- Open Access
Aging increases ovarian cancer growth, metastasis, and immunosuppression that can be alleviated by inhibiting hedgehog signaling
Ovarian cancer incidence and mortality increase with age, yet how aging shapes tumor progression and the immune microenvironment remains poorly defined. Using orthotopic syngeneic models of distinct cellular origins (ovarian surface epithelial and fallopian tube-derived) in young versus aged mice, we show that aged hosts exhibit higher tumor burden, metastasis and ascites. Follicle depletion in young mice did not recapitulate these effects, indicating contributions beyond hormonal decline. Spatial transcriptomics revealed distinct age dependent intratumoral heterogeneity, with Hedgehog signaling enrichment in CD45 + cells from aged tumors, alongside elevated CD206 + tumor-associated macrophages and FoxP3 + regulatory T cells. Pharmacologic Hedgehog inhibition in aged mice suppressed tumor growth, reduced metastasis, and decreased CD206 + macrophages and FoxP3 + T cells while preserving CD8 + T cells. In human ovarian cancer, Hedgehog activation correlated with immunosuppressive and immune checkpoint resistance signatures. We propose Hedgehog inhibition as an immunomodulatory strategy for Hedgehog activated or post menopausal ovarian cancer.
Open AccessAging increases ovarian cancer growth, metastasis, and immunosuppression that can be alleviated by inhibiting hedgehog signaling
Ovarian cancer incidence and mortality increase with age, yet how aging shapes tumor progression and the immune microenvironment remains poorly defined. Using orthotopic syngeneic models of distinct cellular origins (ovarian surface epithelial and fallopian tube-derived) in young versus aged mice, we show that aged hosts exhibit higher tumor burden, metastasis and ascites. Follicle depletion in young mice did not recapitulate these effects, indicating contributions beyond hormonal decline. Spatial transcriptomics revealed distinct age dependent intratumoral heterogeneity, with Hedgehog signaling enrichment in CD45 + cells from aged tumors, alongside elevated CD206 + tumor-associated macrophages and FoxP3 + regulatory T cells. Pharmacologic Hedgehog inhibition in aged mice suppressed tumor growth, reduced metastasis, and decreased CD206 + macrophages and FoxP3 + T cells while preserving CD8 + T cells. In human ovarian cancer, Hedgehog activation correlated with immunosuppressive and immune checkpoint resistance signatures. We propose Hedgehog inhibition as an immunomodulatory strategy for Hedgehog activated or post menopausal ovarian cancer.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of the IHC staining of HCK in ovarian cancer tissue microarrays.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of the IHC staining of HCK in ovarian cancer tissue microarrays.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Table S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Table S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S4 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The effect of GSIs on NOTCH3 ICD expression in HGSOC cells following HCK overexpression.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S4 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The effect of GSIs on NOTCH3 ICD expression in HGSOC cells following HCK overexpression.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Distribution of clinical features associated with poor and good prognostic HGSOC patient samples in the TCGA U133A dataset.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Distribution of clinical features associated with poor and good prognostic HGSOC patient samples in the TCGA U133A dataset.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Cell line selection and engineering
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Cell line selection and engineering
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Fig S2 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFig S2 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.